---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-074323"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T14:13:15.279440+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed Pharmaceuticals raises ~$6M in private placement at $3.30/share, priced at premium to market

## Summary
- Raised ~$6M gross via sale of 1,818,185 shares/pre-funded warrants at $3.30 per share.
- Issued preferred investment options to buy up to 3,272,733 shares at $3.044/sh, expiring in 7 years.
- Investors cancelled prior options for ~1.38M shares, partially offsetting dilution.
- Placement agent H.C. Wainwright received options for 118,182 shares at $4.125/sh.
- Proceeds to fund pipeline development, manufacturing, IP, and general working capital.

## SEC filing metadata
- accession: 0001213900-22-074323
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/ea169087-8k_inmedpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-074323
- JSON: https://secwatch.observer/filing/0001213900-22-074323.json
- Plain text: https://secwatch.observer/filing/0001213900-22-074323.txt

## Key facts
- Material Agreements
  InMed Pharmaceuticals Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-11-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Effective: 2022-11-17
  source text: In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers, dated November 17, 2022 (the “Registration Rights Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm
- Material Agreements
  InMed Pharmaceuticals Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2022-09-09).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2022-09-09
  source text: The Company entered into an engagement letter with Wainwright, dated September 9, 2022 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent, advisor or underwriter in certain offerings, including the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm
- Material Agreements
  InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors valued at approximately $6.0 million (effective 2022-11-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two institutional accredited investors
  - Value: approximately $6.0 million
  - Effective: 2022-11-17
  source text: On November 17, 2022, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 1,818,185 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.